Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | STAT1 | P42224 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.53 |
| ▸ | LDHA | P00338 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | GUSB | P08236 | 1/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30930846 | 1.00 | KDM4E (0.60) | KDM4EALDH1A1HPGDMAPTRAB9A | |
| SCHEMBL21074730 | 0.77 | CHRNB4 (0.52) | HPGDCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL21074662 | 0.76 | CHRNB2 (0.59) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL24075261 | 0.73 | RAB9A (0.73) | KDM4EALDH1A1HPGDMAPTRAB9A | |
| SCHEMBL21074617 | 0.72 | CHRNB2 (0.54) | KDM4ERAB9ANPC1CHRNB2CHRNA4 | |
| SCHEMBL9834209 | 0.71 | MAPT (0.56) | KDM4EALDH1A1HPGDMAPTRAB9A | |
| SCHEMBL3424060 | 0.70 | MAPT (0.70) | KDM4EALDH1A1HPGDMAPTRAB9A | |
| SCHEMBL8054731 | 0.70 | MAPT (0.67) | KDM4EALDH1A1HPGDMAPTRAB9A | |
| SCHEMBL3424059 | 0.70 | MAPT (0.67) | KDM4EALDH1A1HPGDMAPTRAB9A | |
| SCHEMBL3333868 | 0.70 | KDM4E (0.67) | KDM4EALDH1A1HPGDMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3706743-A1 | MODIFIED LIGAND-GATED ION CHANNELS AND METHODS OF USE | Howard Hughes Medical Institute (US) | 2020-09-16 | — | — | EP | claimed |
| US-12247064-B2 | Modified ligand-gated ion channels and methods of use | HOWARD HUGHES MEDICAL INSTITUTE (US) | 2025-03-11 | — | — | US | disclosed |
| US-20210206831-A1 | MODIFIED LIGAND-GATED ION CHANNELS AND METHODS OF USE | HOWARD HUGHES MEDICAL INSTITUTE | 2021-07-08 | — | — | US | disclosed |
| US-20210206831-A1 | MODIFIED LIGAND-GATED ION CHANNELS AND METHODS OF USE | HOWARD HUGHES MEDICAL INSTITUTE | 2021-07-08 | — | — | US | disclosed |
| US-10961296-B2 | Modified ligand-gated ion channels and methods of use | HOWARD HUGHES MEDICAL INSTITUTE (US) | 2021-03-30 | — | — | US | disclosed |
| US-10961296-B2 | Modified ligand-gated ion channels and methods of use | HOWARD HUGHES MEDICAL INSTITUTE (US) | 2021-03-30 | — | — | US | disclosed |
| EP-3706743-A1 | MODIFIED LIGAND-GATED ION CHANNELS AND METHODS OF USE | Howard Hughes Medical Institute (US) | 2020-09-16 | — | — | EP | disclosed |
| US-20190169264-A1 | MODIFIED LIGAND-GATED ION CHANNELS AND METHODS OF USE | HOWARD HUGHES MEDICAL INSTITUTE | 2019-06-06 | — | — | US | disclosed |
| US-20190169264-A1 | MODIFIED LIGAND-GATED ION CHANNELS AND METHODS OF USE | HOWARD HUGHES MEDICAL INSTITUTE | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12247064-B2 | Modified ligand-gated ion channels and methods of use | GRIK4, GRIK2, GRIK5 | KDM4E 4061/4885ALDH1A1 3969/4885HPGD 3928/4885 |
| US-20210206831-A1 | MODIFIED LIGAND-GATED ION CHANNELS AND METHODS OF USE | GRIK4, GRIK2, GRIK5 | KDM4E 4061/4885ALDH1A1 3969/4885HPGD 3928/4885 |
| US-20190169264-A1 | MODIFIED LIGAND-GATED ION CHANNELS AND METHODS OF USE | GRIK4, GRIK2, GRIK5 | KDM4E 4061/4885ALDH1A1 3969/4885HPGD 3928/4885 |
| US-10961296-B2 | Modified ligand-gated ion channels and methods of use | GRIK4, GRIK2, GRIK5 | KDM4E 4061/4885ALDH1A1 3969/4885HPGD 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.